You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HRD

Showing 1 - 25 of 182
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Cancer Trial in France (tests to determine HRD status)

Not yet recruiting
  • Ovarian Cancer
  • tests to determine HRD status
  • Amiens, France
  • +3 more
Nov 22, 2023

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer Trial in Guangzhou (Fluzoparib, Fluzoparib+Camrelizumab)

Recruiting
  • Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
  • Guangzhou, Guangdong, China
    Sun-yat sen university cancer center
Jan 27, 2023

Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Trial in Beijing (Niraparib)

Recruiting
  • Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
  • Beijing, Beijing, China
    Peking University Cancer Hospital
Nov 15, 2023

Carcinoma, Ovarian Epithelial Trial in San Fermo Della Battaglia, Padova (Olaparib, Bevacizumab)

Recruiting
  • Carcinoma, Ovarian Epithelial
  • San Fermo Della Battaglia, Como, Italy
  • +1 more
Nov 2, 2023

Breast Cancer, Ovarian Cancer, Pancreas Cancer Trial (TNG348, Olaparib)

Not yet recruiting
  • Breast Cancer
  • +7 more
  • (no location specified)
Sep 26, 2023

Ovarian Tumors, Ovarian Diseases Trial (Adebrelimab, Fuzuloparib)

Not yet recruiting
  • Ovarian Neoplasms
  • Ovarian Diseases
  • (no location specified)
Feb 23, 2023

Advanced HER2 Negative Breast Carcinoma, HRD+Breast Cancer Trial in Tianjin (fluzoparib+chidamide, fluzoparib+camrelizumab)

Recruiting
  • Advanced HER2 Negative Breast Carcinoma
  • HRD+Breast Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Sep 27, 2022

Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer Trial in Shanghai (Fluzoparib, Irinotecan)

Not yet recruiting
  • Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer
  • Shanghai, Shanghai, China
    Department of Colorectal Surgery Fudan University Shanghai Caner
Feb 22, 2023

Homologous Recombination-related Genesmutationsand HRD in Breast

Not yet recruiting
  • Breast Cancer
  • HER2-low Breast Cancer
  • Standard Management
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jul 18, 2022

es in OVArian Cancer HRD+ Status in Russian Federation

Recruiting
  • Ovarian Cancer
    • Arkhangelsk, Russian Federation
    • +18 more
    Jun 26, 2023

    HRD 100 Gene Expression High, Triple Negative Breast Cancer Trial in Kuala Lumpur (Talazoparib)

    Recruiting
    • HRD 100 Gene Expression High
    • Triple Negative Breast Cancer
    • Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
      University Malaya Medical Centre
    Mar 15, 2022

    Metastatic Castration-resistant Prostate Cancer Trial in Guangzhou (Pamiparib)

    Recruiting
    • Metastatic Castration-resistant Prostate Cancer
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Apr 7, 2022

    HRD Score in Chinese Ovarian Cancer Patients Benefiting From

    Recruiting
    • Ovarian Cancer
      • Shanghai, Shanghai, China
        The Obstetrics and Gynecology Hospital of Fudan University
      Feb 24, 2022

      Variance of HRD From Paired Ovarian Cancer

      Not yet recruiting
      • Ovarian Cancer
      • +2 more
        • Nanjing, Jiangsu, China
          Xiaoxiang Chen
        Sep 25, 2021

        HRD, Cholangiocarcinoma, Metastatic Cancer Trial (Niraparib, Dostarlimab)

        Withdrawn
        • HRD
        • +2 more
        • (no location specified)
        Jun 23, 2022

        Unilateral Inguinal Hernia Trial in Aalst, Ghent (Rebound HRD Mesh)

        Completed
        • Unilateral Inguinal Hernia
        • Rebound HRD Mesh
        • Aalst, Belgium
        • +1 more
        Dec 28, 2022

        HRD and Resistance to PAPPi in EOC Patients

        Recruiting
        • Epithelial Ovarian Cancer
        • +6 more
        • Testing of homologous recombination deficiency
        • Beijing, Beijing, China
          Lei Li
        Mar 26, 2022

        Metastatic Colorectal Cancer Trial in Spain (Olaparib, Pembrolizumab)

        Not yet recruiting
        • Metastatic Colorectal Cancer
        • Sevilla, Andalucia, Spain
        • +14 more
        Aug 2, 2022

        Breast Cancer Trial in Spain (Olaparib)

        Terminated
        • Breast Cancer
        • Barcelona, Spain
        • +7 more
        Jan 18, 2023

        Solid Tumor Trial (CP-506, Carboplatin, Immune checkpoint inhibitor)

        Not yet recruiting
        • Unspecified Adult Solid Tumor, Protocol Specific
        • (no location specified)
        Jun 23, 2022

        HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer

        Completed
        • Epithelial Ovarian Cancer
        • +6 more
        • Evaluation of homologous recombination deficiency score
        • Beijing, Beijing, China
          Lei Li
        Mar 26, 2022

        Mesothelioma, Homologous Recombination Deficiency Trial in Chicago (Olaparib)

        Recruiting
        • Mesothelioma
        • Homologous Recombination Deficiency
        • Chicago, Illinois
          University of Chicago Medical Center
        May 12, 2021

        HRD Cancer, SCLC, Advanced Solid Tumors Trial run by the NCI (Berzosertib, Sacituzumab Govitecan)

        Recruiting
        • HRD Cancer
        • +2 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Jan 20, 2023

        Metastatic Castration-Resistant Prostate Cancer (mCRPC), Homologous Recombination Deficiency (HRD) Trial in Worldwide

        Terminated
        Has Results
        • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
        • Homologous Recombination Deficiency (HRD)
        • Athens, Georgia
        • +8 more
        Oct 20, 2021

        Ovarian Cancer Trial in Vandœuvre-lès-Nancy (HRD and BRCA mutations)

        Completed
        • Ovarian Cancer
        • HRD and BRCA mutations
        • Vandœuvre-lès-Nancy, France
          Institut de Cancerologie de Lorraine
        Mar 29, 2022